Crapo, Bennet, Cardin, and Scott introduce legislation to expand coverage of MCEDs

NHS England will wait to consider NHS rollout of Galleri multi-cancer early detection test

Based on data from the first year of the three-year NHS-Galleri trial, NHS England has decided that it will wait to see final results, expected in 2026, before considering whether an NHS rollout of the Galleri multi cancer early detection test (the Multi Cancer Blood Test Programme) should go ahead.

May 31, 2024

Vol.50 No.22

Clinical

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.

NCI launches research network to evaluate emerging cancer screening technologies

NCI has launched a clinical trials network to evaluate emerging technologies for cancer screening. The Cancer Screening Research Network will support the Biden-Harris administration’s Cancer Moonshot by investigating how to identify cancers earlier.

February 23, 2024

Vol.50 No.08

Regulatory News

Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approval
Meanwhile, NCI trial will assess clinical utility

Multi-cancer detection tests evoke conflicting reactions—the excitement at their promise is quickly dampened by concerns over the uncertainty of their clinical benefit, very low sensitivity for detecting stage 1 cancers, and the risks that come from subsequent workups.

Community Health Network, GRAIL to offer Galleri MCED test in Central Indiana

Indianapolis-based Community Health Network and GRAIL LLC have partnered to offer Galleri, GRAIL’s multi-cancer early detection blood test, to individuals at Community Health Network’s sites of care.

July 01, 2022

Vol.48 No.26

NCI Director's Report

Doug Lowy: NCI to fund MCED research, early-stage investigator diversity in Moonshot 2.0

In the next phase of the Cancer Moonshot, NCI will focus on investing in the development and testing of new modalities, including multi-cancer early detection assays, and fostering diversity in oncology, NCI Acting Director Douglas R. Lowy said at a joint meeting of the Board Of Scientific Advisors and the National Cancer Advisory Board.

June 17, 2022

Vol.48 No.24

By Alice Tracey

Crapo, Bennet, Cardin, and Scott introduce legislation to expand coverage of MCEDs

YOU MAY BE INTERESTED IN

NHS England will wait to consider NHS rollout of Galleri multi-cancer early detection test

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

NCI launches research network to evaluate emerging cancer screening technologies

Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approval
Meanwhile, NCI trial will assess clinical utility

Community Health Network, GRAIL to offer Galleri MCED test in Central Indiana

Doug Lowy: NCI to fund MCED research, early-stage investigator diversity in Moonshot 2.0

Renew today!

Subscriber content

Login

Crapo, Bennet, Cardin, and Scott introduce legislation to expand coverage of MCEDs

YOU MAY BE INTERESTED IN

NHS England will wait to consider NHS rollout of Galleri multi-cancer early detection test

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

NCI launches research network to evaluate emerging cancer screening technologies

Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approvalMeanwhile, NCI trial will assess clinical utility

Community Health Network, GRAIL to offer Galleri MCED test in Central Indiana

Doug Lowy: NCI to fund MCED research, early-stage investigator diversity in Moonshot 2.0

Login

Heated discussion breaks out in recent meeting as FDA mulls standards for MCD approval
Meanwhile, NCI trial will assess clinical utility